DR-299 MutSig – The incidence and co-ocurrence of genomic biomarkers in metastatic tumors

No Featured Image set

The observed incidence of cancer biomarkers can influence resource investment into key areas such as drug discovery and companion diagnostic technology. The list of clinically relevant cancer biomarkers is growing, however a systematic description of the incidence of these biomarkers is currently lacking. Understanding the prevalence of these biomarkers in late-stage cancer can be especially relevant since many companion diagnostics are utilized in the treatment of stage III and IV cancers.

By using multiple publicly available knowledge management resources that describe clinically relevant alterations, we aim to characterize the frequency of these biomarkers and contextualize their associations within the Hartwig dataset. 

Eivind Hovig,  University of Oslo, Norge

Back to news

More news

Whole Genome Sequencing on Cerebrospinal Fluid: No Biopsy, Yet a Report 

Whole Genome Sequencing on Cerebrospinal Fluid: No Biopsy, Yet a Report 

07-11-2024

Whole genome sequencing is typically only performed on tissue biopsies. In collaboration with Hartwig Medical Foundation, a clinical molecular biologist …

Hartwig Medical Foundation welcomes Eliëtte Vaal to its Supervisory Board  

Hartwig Medical Foundation welcomes Eliëtte Vaal to its Supervisory Board  

25-04-2025

Hartwig Medical Foundation (Hartwig) has welcomed Eliëtte Vaal as a new member of its Supervisory Board. Her appointment reflects Hartwig’s …

Clinical Cancer Genomics 2025: a cheerful boost for this rapidly emerging field 

Clinical Cancer Genomics 2025: a cheerful boost for this rapidly emerging field 

24-03-2025

The Clinical Cancer Genomics Conference 2025 took place on 20–21 March 2025 in Amsterdam. The event website ccg2025.eu has been retired, but …

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl